-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.
-
Flerie går in som ny storägare i Lipum
Det Umeåbaserade biofarmabolaget Lipum tar in 39 miljoner kronor genom en riktad nyemission. För merparten av beloppet står Flerie Invest, som därmed blir största ägare.
-
Investments worth 40 billion in the Öresund region – “A huge investment wave”
A new report reveals that medical companies in the Oresund region are investing like never before.